New combo therapy for tough prostate cancer shows promise in early trial
NCT ID NCT03737370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two drugs—docetaxel (a chemotherapy) and radium 223 (a radioactive drug)—in 43 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goal was to find the safest dose and watch for side effects. Researchers also tracked how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Docetaxel (chemotherapy) and Radium 223 (radioactive drug)
What this could lead to
If successful, this could lead to a safer and more effective combination treatment for men with advanced prostate cancer that has spread to the bones.
What could go wrong
This is an early phase 1 trial focused on safety and dosing, not on proving the treatment works. The combination may cause serious side effects like low blood cell counts or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Lahey Hospital & Medical Center
Boston, Massachusetts, 01805, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States